Biopsy-Guided arthritis treatment: a step toward personalized care?
NCT ID NCT05379322
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study aimed to see if analyzing joint tissue (synovial biopsies) could help doctors pick the best biologic drug for people with rheumatoid arthritis who had not responded to standard treatments. It planned to assign patients to either an anti-TNF or a JAK inhibitor based on their tissue type. However, the trial was withdrawn before enrolling any participants, so no results are available.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 3
Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.
- Started
-
Mar 2023
- Expected to finish
-
Mar 2023
An estimate. End dates often move.
- Lead sponsor
-
A government agency
The lead sponsor is a government body.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Subject should be capable of consent * Age 18 and older * Classified as rheumatoid arthritis as per EULAR/ACR criteria 2010 * Failed one DMARD (Methotrexate, leflunomide, Sulfalsalazine, hydroxychloroquine) * Can be on steroid dose \<7.5mg * Quantiferon negative * Hepatitis B, C negative * No recent history (\<5y) of malignancy Exclusion Criteria: * Overlap syndrome * Previously treated with a biological medication * Heart failure NYHA III/IV * Active tuberculosis * Active infections * Previous history of DVT, PE, or Stroke * Other significant comorbidities that will prevent them from taking any biologic medication as per EULAR guidelines on treating rheumatoid arthritis 2020. * Pregnancy
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Rheumatoid arthritis are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Abu Dhabi Stem Cells Center
Abu Dhabi, Abu Dhabi Emirate, 4600, United Arab Emirates
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Scientists probe why rheumatic pain feels different for everyone
- A new ankle? researchers track 400 people with an implant meant to restore movement
- Can a Job-Focused rehab program keep arthritis patients employed?
- Do rheumatic diseases quietly damage the Eye's oil glands?
- Hidden kidney damage may lurk in rheumatoid arthritis patients
- Can a new injection calm rheumatoid arthritis? an early trial puts ZB002 to the test